Hepatitis C Information - Novelos Therapeutics Closes $15 Million Private Placement

Novelos Therapeutics Closes $15 Million Private Placement
Genetic Engineering News - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, announced that today, it closed its previously announced private placement resulting in $15.06 million in

Clinical Trial Results Show That Peregrine's First-In-Class Anti-Viral
Medical News Today - Peregrine Pharmaceuticals, Inc. (PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it will present top line data demonstrating that its first-in

euro adhoc: Intercell AG / Financial Figures
VWDNews - Vienna (Austria), March 6, 2006 - Vaccine company Intercell AG (VSE: ICLL) today announced its preliminary 2005 full year results. Intercell?s aggregate annual revenues increased from EUR 4.6 million in 2004 to EUR 8.5 million in 2005, or by 84.9